BR0112390A - Manipulação de vìrus de rna de filamento negativo por rearranjo de seus genes e usos dos mesmos - Google Patents

Manipulação de vìrus de rna de filamento negativo por rearranjo de seus genes e usos dos mesmos

Info

Publication number
BR0112390A
BR0112390A BR0112390-4A BR0112390A BR0112390A BR 0112390 A BR0112390 A BR 0112390A BR 0112390 A BR0112390 A BR 0112390A BR 0112390 A BR0112390 A BR 0112390A
Authority
BR
Brazil
Prior art keywords
genes
virus
rearrangement
manipulation
rna viruses
Prior art date
Application number
BR0112390-4A
Other languages
English (en)
Inventor
Gail W Wertz
Andrew L Ball
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Publication of BR0112390A publication Critical patent/BR0112390A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20261—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"MANIPULAçãO DE VìRUS DE RNA DE FILAMENTO NEGATIVO POR REARRANJO DE SEUS GENES E USOS DOS MESMOS". A presente invenção fornece um processo para aumentar a expressão de um gene distante do promotor em um vírus da ordem Mononegavirales e um vírus recombinante construído através de tal processo. é também fornecido um processo para atenuar um vírus da ordem Mononegavirales e para construir um vírus atenuado útil para uma vacina.
BR0112390-4A 2000-06-23 2001-06-22 Manipulação de vìrus de rna de filamento negativo por rearranjo de seus genes e usos dos mesmos BR0112390A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/602,288 US6596529B1 (en) 1997-05-02 2000-06-23 Manipulation of negative stranded RNA viruses by rearrangement of their genes and uses thereof
PCT/US2001/019901 WO2002000868A1 (en) 2000-06-23 2001-06-22 Manipulation of negative stranded rna viruses by rearrangement of their genes and uses thereof

Publications (1)

Publication Number Publication Date
BR0112390A true BR0112390A (pt) 2003-09-23

Family

ID=24410755

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112390-4A BR0112390A (pt) 2000-06-23 2001-06-22 Manipulação de vìrus de rna de filamento negativo por rearranjo de seus genes e usos dos mesmos

Country Status (11)

Country Link
US (3) US6596529B1 (pt)
EP (1) EP1292329A4 (pt)
JP (1) JP2004501639A (pt)
KR (2) KR20080106485A (pt)
CN (1) CN1441842A (pt)
AU (1) AU2001270056A1 (pt)
BR (1) BR0112390A (pt)
CA (1) CA2413800A1 (pt)
IL (1) IL153388A0 (pt)
MX (1) MXPA03000061A (pt)
WO (1) WO2002000868A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE418729T1 (de) 2002-08-22 2009-01-15 Applera Corp Verfahren zur charakterisierung von biomolekülen mittels resultat-gesteuerter strategie
EP1633860A2 (en) 2003-06-09 2006-03-15 Wyeth IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA
AU2005206410A1 (en) * 2004-01-22 2005-08-04 Dnavec Research Inc. Method of producing minus strand RNA virus vector with the use of hybrid promoter containing cytomegalovirus enhancer and avian beta-actin promoter
CA2561245C (en) 2004-04-09 2013-06-18 Wyeth Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof
US7405396B2 (en) * 2005-05-13 2008-07-29 Applera Corporation Sample handling mechanisms and methods for mass spectrometry
US7351959B2 (en) * 2005-05-13 2008-04-01 Applera Corporation Mass analyzer systems and methods for their operation
US7385186B2 (en) * 2005-05-13 2008-06-10 Applera Corporation Methods of operating ion optics for mass spectrometry
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
CN105441483B (zh) * 2005-10-14 2019-05-10 美国政府健康及人类服务部，疾病控制和预防中心 狂犬病病毒组合物和方法
CN105769931B (zh) * 2006-09-15 2021-04-27 渥太华医院研究机构 溶瘤弹状病毒
EP2097517B1 (en) 2006-10-16 2014-06-04 Genelux Corporation Recombinant Lister strain vaccinia virus encoding an anti-VEGF single chain antibody
EP2069485A4 (en) * 2007-07-13 2011-05-25 Medimmune Llc PREPARATION OF NEGATIVE STRAND RNA VIRUSES BY ELECTROPORATION
JP5045416B2 (ja) * 2007-12-17 2012-10-10 富士通株式会社 光導波路素子およびそれを用いた光学装置
US20090162321A1 (en) * 2007-12-20 2009-06-25 Wyeth Methods for packaging propagation-defective vesicular stomatitis virus vectors using a stable cell line that expresses g protein
US20090175900A1 (en) * 2007-12-20 2009-07-09 Wyeth Methods for packaging propagation-defective vesicular stomatitis virus vectors
US20090175906A1 (en) * 2007-12-21 2009-07-09 Wyeth Genetically Modified Attenuated Vesicular Stomatitis Virus, Compositions and Methods of use Thereof
US9610346B2 (en) 2012-03-23 2017-04-04 International Aids Vaccine Initiative Recombinant viral vectors
WO2017100756A1 (en) * 2015-12-11 2017-06-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant respiratory syncytial virus strains comprising ns1 and ns2 gene shifts
CN107557340A (zh) * 2017-09-26 2018-01-09 南京普菲科医药科技有限公司 一种可诱导性拯救弹状病毒的细胞系及其构建方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11512609A (ja) * 1995-09-27 1999-11-02 アメリカ合衆国 クローン化されたヌクレオチド配列からの感染性ＲＳウイルス（ｒｅｓｐｉｒａｔｏｒｙ ｓｙｎｃｙｔｉａｌ ｖｉｒｕｓ）の生産
US6923971B2 (en) * 1995-09-27 2005-08-02 The United States Of America As Represented By The Department Of Health & Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
JP4413999B2 (ja) * 1996-07-15 2010-02-10 アメリカ合衆国 クローニングされたヌクレオチド配列からの弱毒化呼吸シンシチウムウィルスワクチンの製造
EP1005535B1 (en) * 1997-05-02 2015-11-11 The Uab Research Foundation Attenuation of negative stranded rna viruses by rearrangement of their genes and uses thereof

Also Published As

Publication number Publication date
KR20080106485A (ko) 2008-12-05
EP1292329A1 (en) 2003-03-19
WO2002000868A1 (en) 2002-01-03
KR20030071482A (ko) 2003-09-03
CN1441842A (zh) 2003-09-10
MXPA03000061A (es) 2004-09-13
US20040235135A1 (en) 2004-11-25
JP2004501639A (ja) 2004-01-22
US20030166254A1 (en) 2003-09-04
US6777220B2 (en) 2004-08-17
AU2001270056A1 (en) 2002-01-08
IL153388A0 (en) 2003-07-06
US6596529B1 (en) 2003-07-22
CA2413800A1 (en) 2002-01-03
EP1292329A4 (en) 2005-11-16

Similar Documents

Publication Publication Date Title
BR0112390A (pt) Manipulação de vìrus de rna de filamento negativo por rearranjo de seus genes e usos dos mesmos
BR9913935A (pt) Métodos de tratamento e prevenção de infecção causada por pelo menos um vìrus da famìlia dos flaviviridae e doença associada com a dita infecção em um hospedeiro vivo
BR9712138A (pt) Vìrus de rna isolado, vacina, processo para imunizr um indivìduo para induzir proteção contra um vìrus de rna não segmentado, sentido negativo, de filamento único, da ordem mononegavirales e para produzir vìrus de rna, molécula de ácido nucleico isolada e composição.
HUP0102441A2 (hu) Megváltozott interferon-antagonista aktivitással rendelkező, legyengített negatívszálú vírusok vakcinaként és gyógyszerként való alkalmazásra
BR9812232A (pt) Vìrus sincicial respiratório (rsv) humano subgrupo b, isolado, recombinantemente gerado , atenuado, vacina, processo para imunizar um indivìduo para induzir proteção contra o rsv subgrupo b, composição, processo para produzir rsv subgrupo b infeccioso atenuado, e, molécula isolada de ácido nucleico
ATE138384T1 (de) Olionukleotidalkylphosphonate und - phosphonothioate
BR0111732A (pt) Prodrogas de 2-deóxi-beta-l-nucleosìdeos
DE69333937D1 (de) Nukleinsäuren und sie verwendende verfahren zur bekämpfung viraler pathogene
WO2004028471A3 (en) Influenza therapeutic
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
FR11C0027I1 (fr) Virus de l'influenza recombinants pour vaccins et traitement genetique
PT100472A (pt) Sequencias genomicas do virus da hepatite c e composicoes farmaceuticas que as contem, para diagnostico e terapeutica da hepatite c
ES2107609T3 (es) Polipeptidos sinteticos como inhibidores de vih-1.
EA201000085A1 (ru) dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ
DE69636863D1 (de) Benutzung von immunmodulatoren zur herstellung von medikamenten zur inhibierung einer immunantwort gegen gleichzeitig verabreichte rekombinante viren
MX9202512A (es) Virus de avipox recombinante, cultivo de celulas infectadas por este virusy vacunas para las aves de corral derivadas de este virus.
BR0316244A (pt) Vacina de polinucleotìdeo, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina de polinucleotìdeo
FI890116A0 (fi) Icke-reverterande rna-virus.
BR9707400A (pt) Vacinas contra produto do gene 63 de vìrus varicella zoster.
De Martino et al. Interference of bovine herpesvirus 1 (BHV‐1) in sorbitol‐Induced apoptosis
AR002006A1 (es) Un proceso para la purificacion de un antigeno de superficie de hepatitis b viral que comprende un peptido pres2
ES2132330T3 (es) Vacuna para la proteccion de caballos frente a la infeccion por el virus del herpes equino.
SG136969A1 (en) Influenza therapeutic
RU2099086C1 (ru) Способ профилактики гриппа у детей живой гриппозной вакциной
BR9205877A (pt) Processo e composiçao para o tratamento de infecçoes por herpes.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.